Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1…

Amount: Not stated
Type: Grant

Key facts

Key facts for Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Amount	Not stated
Issuer	National Institutes of Health
Who can apply	US companies
Sectors	EdTech · HealthTech
Deadline	Closes 07 Jan 2027

Unlock application details

See all eligibility criteria, required documents and the official application link. Free account, no card.

Update history

Source: grants.gov ↗

Source checked 2 days ago

40 days agoagentImported from the official source

Opportunities with the same funding type or region
AI Growth Lab		Closes 27 Sep 2026
BJA FY 2026 Adult Treatment Court Program	up to $2.5M	Closes 30 Oct 2026
BJA FY 2026 Capital Case Litigation Initiative: Improving the Quality of Legal Representation in State Capital Cases	up to $450,000	Closes 29 Oct 2026